Evidence map›Paper›PMID 29574328›Full record

ArticleTranslational oncology2018

The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy.

Hua Zhang, Erich Sturgis, Lijun Zhu, Zhongming Lu, Ye Tao, Hongliang Zheng, Guojun Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Hua ZhangDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Otolaryngology-Head and Neck Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai,China.
Erich SturgisDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Lijun ZhuDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Oral and Maxillofacial Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhongming LuDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Otolaryngology-Head and Neck Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Ye TaoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Otolaryngology-Head and Neck Surgery, the 2nd affiliated hospital of Anhui Medical University, Hefei, China.
Hongliang ZhengDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. Electronic address: zheng_hl2004@163.com.
Guojun LiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: gli@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USAnhui Medical University · CNGuangdong Academy of Medical Sciences · CNGuangdong General Hospital · CNSecond Military Medical University · CNYuhuangding Hospital · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2002 to 2012
$26.1M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Molecular Epidemiology of Head and Neck CancerR01ES011740 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2001 to 2012
$6.3M
Genotypes and Phenotypes of Apoptosis and Risk of Head and Neck CancerR01CA131274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2009 to 2013
$3.0M
Immuno-inflammatory Response Non-coding RNAs as Predictors of HPV Status & Outcome of Oropharyngeal Cancer PatientsR01CA236859 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2020 to 2024
$1.5M
Predictors of HPV16 Status and Outcomes of Oropharyngeal Cancer PatientsK07CA133099 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2008 to 2012
$680k
Inflammatory Response miRNAs Predict HPV-associated Oropharyngeal Cancer OutcomeR03CA186261 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2015 to 2016
$164k
Cytokine Variants as Predictors of HPV-16 Status & Outcome of Oropharyngeal CanceR03CA135679 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2008 to 2009
$154k
NCI NIH HHS K07 CA133099NCI NIH HHS K12 CA088084NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA131274NCI NIH HHS R01 CA236859NCI NIH HHS R03 CA135679NCI NIH HHS R03 CA186261NIEHS NIH HHS R01 ES011740
6 · The paper itself

Abstract

Human papillomavirus (HPV) activates E2F1-driven transcription via the E7-RB-E2F1 pathway. A polymorphism in the 3' UTR of E2F1 gene may disrupt a binding site for miRNA and may affect its transcription level, thus modifying the susceptibility to radiotherapy and outcomes through this pathway. We evaluated the association of a polymorphism at the 3'UTR miRNA binding site of E2F1 gene (rs3213180) with risk of recurrence of SCCOP in a cohort of 1008 patients. Log-rank test and univariate and multivariable Cox models were used to evaluate the associations. Compared with patients with E2F1-rs3213180 GG homozygous genotype, the patients with E2F1-rs3213180GC+CC variant genotypes had significantly better disease-free survival (log-rank P<.001) and decreased risk of SCCOP recurrence (HR, 0.4, 95% CI, 0.3-0.5) after multivariable adjustment. Furthermore, among patients with HPV16-positive tumors, the patients with E2F1-rs3213180 GC+CC variant genotypes had significantly better disease-free survival rates (log-rank P<.001) and lower recurrence risk than those with E2F1-rs3213180 GG homozygous genotype (HR, 0.2, 95% CI, 0.1-0.4). Our findings suggest that E2F1-rs3213180 polymorphism may modulate the risk of recurrence in SCCOP patients, particularly for patients with HPV16-positive tumors of SCCOP. However, future larger population and functional studies are warranted to validate these results.

Identifiers

PMID29574328
PMCPMC6078938
OpenAlexW2789914151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.